Confronto

AOD-9604 vs. Tesamorelin

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Crescita

N. CAS

221231-10-3

901758-09-6

Peso molecolare

1815.09 g/mol

5135.83 g/mol

Emivita

0.4 h

Sequenza

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

Meccanismo d'azione

AOD-9604

AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.

Tesamorelin

Tesamorelin is an N-terminally modified 44-amino-acid version of human GHRH(1-44). A 3-hexenoyl modification protects against rapid dipeptidyl-peptidase-IV cleavage. Binding to the pituitary GHRH receptor stimulates endogenous pulsatile growth-hormone secretion and consequently hepatic IGF-1 production.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	AOD-9604	Tesamorelin
Australia	Limitato	—
Canada	—	Su prescrizione
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between AOD-9604 and Tesamorelin?: AOD-9604 is classified as "Crescita", while Tesamorelin is classified as "Crescita". AOD-9604: Synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH 176-191). Originally developed by Metabolic Pharmaceuticals as an oral obesity therapy; all phase-2 trials missed the primary endpoint. No marketing approval. The Australian TGA Schedule 4 classification is often misunderstood. Tesamorelin: Stabilised GHRH analog (growth-hormone-releasing hormone). FDA-approved in 2010 as Egrifta for reduction of abdominal lipohypertrophy in HIV-associated lipodystrophy. Not approved for the general population. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, AOD-9604 or Tesamorelin?: The highest available evidence level is "RCT sull'uomo" for AOD-9604 and "RCT sull'uomo" for Tesamorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of AOD-9604 and Tesamorelin in Germany and the United States?: Germania: AOD-9604 — Non approvato, Tesamorelin — Non approvato. Stati Uniti: AOD-9604 — Non approvato, Tesamorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

AOD-9604

Tesamorelin

Australia

Limitato

—

Canada

—

Su prescrizione

Germania

Non approvato

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between AOD-9604 and Tesamorelin?

AOD-9604 is classified as "Crescita", while Tesamorelin is classified as "Crescita". AOD-9604: Synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH 176-191). Originally developed by Metabolic Pharmaceuticals as an oral obesity therapy; all phase-2 trials missed the primary endpoint. No marketing approval. The Australian TGA Schedule 4 classification is often misunderstood. Tesamorelin: Stabilised GHRH analog (growth-hormone-releasing hormone). FDA-approved in 2010 as Egrifta for reduction of abdominal lipohypertrophy in HIV-associated lipodystrophy. Not approved for the general population. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, AOD-9604 or Tesamorelin?

The highest available evidence level is "RCT sull'uomo" for AOD-9604 and "RCT sull'uomo" for Tesamorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of AOD-9604 and Tesamorelin in Germany and the United States?

Germania: AOD-9604 — Non approvato, Tesamorelin — Non approvato. Stati Uniti: AOD-9604 — Non approvato, Tesamorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.